乳腺癌内分泌治疗的相关进展

doi:10.6040/j.issn.1671-7554.0.2017.898

摘要/Abstract

摘要： 内分泌治疗是激素受体阳性乳腺癌的主要治疗手段。随着一些重要临床试验证据的出现,内分泌治疗的策略也不断得到更新,包括早期乳腺癌辅助内分泌治疗的延长,卵巢功能抑制的联合应用等,进一步改善了患者的生存。内分泌耐药机制研究的不断深入也为晚期乳腺癌的内分泌治疗提供了新的治疗手段,随着新的药物被开发,包括雌激素受体下调剂、内分泌联合靶向治疗药物的应用,明显改善了患者的预后,显示出良好的临床应用前景。

关键词: 乳腺癌, 激素受体阳性, 内分泌治疗, 靶向治疗, 预后

Abstract: Endocrine therapy is the mainstay treatment for hormone-receptor-positive breast cancer. Based on new evid-ences collected from clinical trials, new strategies have been available and have improved the long-term outcomes of patients, including longer endocrine treatment of early breast cancer, combined use of ovarian suppression, and so on. In parallel with expanding knowledge about the resistance mechanisms to endocrine therapy, new agents for hormone receptor-positive metastatic breast cancer continue to appear. The selective estrogen-receptor degrader, fulvestrant, and new endocrine-target combinations provide significant and clinically meaningful improvements in outcomes. This review will explore the current and investigational approaches to endocrine therapy for hormone-receptor-positive breast cancer.

Key words: Breast cancer, Hormone receptor positive, Endocrine therapy, Target therapy, Prognosis

中图分类号:

R737.9

凌瑞,张聚良. 乳腺癌内分泌治疗的相关进展[J]. 山东大学学报 (医学版), 2018, 56(1): 27-31.

LING Rui, ZHANG Juliang. Advances of endocrine therapy for hormone-receptor-positive breast cancer[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 27-31.

参考文献

[1] Early Breast Cancer Trialists Collaborative Group(EBC-TCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials[J]. Lancet, 2011, 378(9793): 771-784.
[2] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
[3] Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[J]. J Clin Oncol, 2013, 31: 5.
[4] Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer[J]. N Engl J Med, 2015, 372(5): 436-446.
[5] Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression(TEXT and SOFT): a combined analysis of two phase 3 randomised trials[J]. Lancet Oncol, 2015, 6(7): 848-858.
[6] Regan MM, Francis PA, Pagani O. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials[J]. J Clin Oncol, 2016, 34(19): 2221-2231.
[7] Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med, 2016, 375(3): 209-219.
[8] Mamounas EP, Lembersky B, Jeong JH, et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor(AI)or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer[J]. J Clin Breast Cancer, 2006, 7(5): 416-421.
[9] Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy(DATA): a randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18(11): 1502-1511.
[10] Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial(BOOG 2006-05)[J]. J Natl Cancer Inst, 2018, 110(1). doi: 10.1093/jnci/djx134.
[11] Nabholtz JM, Buzdar A, Pollak M, et al.Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group[J]. J Clin Oncol, 2000, 18(22): 3758-3767.
[12] Thürlimann B, Hess D, Köberle D, et al. Anastrozole(‘Arimidex’)versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET(Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability)trial[J]. Breast Cancer Res Treat, 2004, 85(3): 247-254.
[13] Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group[J]. J Clin Oncol, 2008, 26: 4883-4890.
[14] Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study[J]. Breast Cancer Res Treat, 2012, 136(2): 503-511.
[15] Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer(FALCON): an international, randomised, double-blind, phase 3 trial[J]. Lancet, 2016, 388(10063): 2997-3005.
[16] Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J]. J Clin Oncol, 2012, 30(16): 1919-1925.
[17] Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer[J]. N Engl J Med, 2012, 367(5): 435-444.
[18] Fribbens C, OLeary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2016, 34(25): 2961-2968.
[19] Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.
[20] Kornblum NS, Manola J, Klein P, et al. PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor(HR)-positive, HER2-negative metastatic breast cancer(MBC)resistant to aromatase inhibitor(AI)therapy[EB/OL].[2016 SABCS S1-02]. https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf
[21] Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer(BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(7): 904-916.
[22] Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18[J]. Breast Cancer Res, 2016, 18(1): 67.
[23] Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med, 2016, 375(20): 1925-1936.
[24] Romero D. Breast cancer: MONALEESA-2 and FALCON-PFS advantage[J]. Nat Rev Clin Oncol, 2016, 13(12): 717.
[25] Iwata H, Im SA, Masuda N, et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients[J]. J Glob Oncol, 2017, 3(4): 289-303.
[26] Rita N, Minetta CL, Douglas Y, et al. Permbrolizumab plus standard neoadjuvant therapy for high risk breast cancer: results from the I-SPY2 trial[EB/OL].[2017-ASCOAbs 506]. https://meetinglibrary.asco.org/record/153653/abstract.

相关文章 15

[1]	古春青,郭睿思,周勤勤,刘恒辉,巴婉玉,孙士玲,王冰,郑玉玲,吴宿慧. 基于网络药理学和动物实验探讨酸枣仁-远志药对治疗乳腺癌相关性失眠的作用机制[J]. 山东大学学报 (医学版), 2026, 64(1): 99-108.
[2]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[3]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[4]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[5]	王雪梅,杨豪,宋洋,程世超,张婷婷,王艳春. 抗糖尿病药物与女性恶性肿瘤的因果关联:一项两样本孟德尔随机化分析[J]. 山东大学学报 (医学版), 2025, 63(6): 67-77.
[6]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[7]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[8]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[9]	刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[10]	陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[11]	余之刚,郑超. 乳腺癌多学科诊疗的现状、挑战与创新模式[J]. 山东大学学报 (医学版), 2025, 63(1): 1-9.
[12]	山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16.
[13]	程跃启,王斐,于理想,郑超,余之刚. 曲妥珠单抗致HER2阳性乳腺癌患者心脏毒性的研究进展[J]. 山东大学学报 (医学版), 2025, 63(1): 17-24.
[14]	王敏, 李习平, 檀军, 邱梅, 侯泽宇, 田莹, 罗鸿莹, 范超文, 齐玲, 俞琦, 谢薇. 慢病毒载体介导Gag-Caspase-8诱导三阴性乳腺癌原代细胞凋亡及S期阻滞[J]. 山东大学学报 (医学版), 2025, 63(1): 25-34.
[15]	张洁,张芳芳,王靖楠,李泽宇,宋颖,李娜. circ_0000144在乳腺癌中的表达及其对乳腺癌细胞增殖、迁移和侵袭能力的影响[J]. 山东大学学报 (医学版), 2025, 63(1): 35-42.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed